Perhexilinum [Inn-Latin] en es it fr

Perhexilinum [Inn-Latin] Brand names, Perhexilinum [Inn-Latin] Analogs

Perhexilinum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Perhexilinum [Inn-Latin] Chemical_Formula


Perhexilinum [Inn-Latin] RX_link

No information avaliable

Perhexilinum [Inn-Latin] fda sheet

Perhexilinum [Inn-Latin] msds (material safety sheet)

Perhexilinum_[Inn-Latin] MSDS

Perhexilinum [Inn-Latin] Synthesis Reference

No information avaliable

Perhexilinum [Inn-Latin] Molecular Weight

277.488 g/mol

Perhexilinum [Inn-Latin] Melting Point

No information avaliable

Perhexilinum [Inn-Latin] H2O Solubility

0.0608 mg/L

Perhexilinum [Inn-Latin] State


Perhexilinum [Inn-Latin] LogP


Perhexilinum [Inn-Latin] Dosage Forms

Tablet for oral administration (100 mg)

Perhexilinum [Inn-Latin] Indication

For the management of severe angina pectoris.

Perhexilinum [Inn-Latin] Pharmacology

Used in the treatment of unresponsive or refractory angina. Perhexiline increases glucose metabolism at the expense of free-fatty-acid metabolism, enhancing oxygen efficiency during myocardial ischaemia. Perhexiline also potentiates platelet responsiveness to nitric oxide both in patients with angina and patients with acute coronary syndrome. The predominant mechanism of this particular perhexiline effect is an increase in platelet cGMP responsiveness. Perhexiline also may reduce the potential for nitric oxide clearance by neutrophil-derived oxygen. Perhexiline relieves symptoms of angina, improves exercise tolerance, and increases the workload needed to induce ischaemia when used as monotherapy. The primary therapeutic roles for perhexiline are as short-term therapy (less than 3 months duration) in patients with severe ischaemia awaiting coronary revascularisation or long-term therapy in patients with ischaemic symptoms refractory to other therapeutic measures.

Perhexilinum [Inn-Latin] Absorption

Well absorbed (>80%) from the gastrointestinal tract following oral administration.

Perhexilinum [Inn-Latin] side effects and Toxicity

Oral LD50 Rat: 2150 mg/kg; Oral LD50 Mouse: 2641 mg/kg. Short term adverse effects include nausea, transient dizziness, hypoglycaemia in diabetic patients, and torsade de pointes (rare).

Perhexilinum [Inn-Latin] Patient Information

No information avaliable

Perhexilinum [Inn-Latin] Organisms Affected

Humans and other mammals